AVO1 Antibody

What is AVO1 and what cellular processes does it regulate?

AVO1 is a component of the Target of Rapamycin Complex 2 (TORC2) in Saccharomyces cerevisiae (baker's yeast). It plays a crucial role in the TORC2 signaling pathway, which regulates actin cytoskeletal dynamics, cell wall integrity, and related cellular processes. AVO1 functions as a direct binding partner of Ypk2 (Yeast Protein Kinase 2), which is a downstream substrate of TORC2 .

The TORC2 complex consists of several components including Tor2, Lst8, Avo1, Avo2, Tsc11 (also known as Avo3), and Bit61. Within this complex, AVO1 serves as a critical mediator that physically couples the kinase activity of TORC2 to its downstream effector Ypk2 . The interaction between AVO1 and Ypk2 has been mapped to an internal region (amino acids 600-840) of AVO1 and a C-terminal region of Ypk2 .

How does AVO1 function within the TORC2 signaling network?

AVO1 functions as a critical scaffold protein within the TORC2 complex. Research has demonstrated that AVO1 directly binds to Ypk2, a downstream AGC-family protein kinase, facilitating TORC2-mediated phosphorylation and subsequent activation of Ypk2 . This activation is essential for:

• Maintaining cell wall integrity

• Regulating actin organization

• Participating in sphingolipid metabolism

The interaction between AVO1 and Ypk2 has been characterized through multiple experimental approaches including GST pulldown assays, in vitro binding experiments, and functional studies in yeast . Disruption of this interaction, as demonstrated by overexpressing a truncated form of Ypk2 (Ypk2 334–677) that competes with full-length Ypk2 for AVO1 binding, leads to phenotypes reminiscent of TORC2 mutants, including defective cell wall integrity and aberrant actin organization .

What is the molecular structure and functional domains of AVO1?

AVO1 is a 1176 amino acid protein that contains several functional domains . Based on interaction studies, a key functional region has been identified between amino acids 600-840, which is responsible for direct binding to Ypk2 . STRING database analysis indicates that AVO1 belongs to the SIN1 family of proteins .

The functional domains of AVO1 include:

The protein is considered essential for yeast viability, as it maintains the integrity of the TORC2 complex and mediates critical signaling functions .

What types of AVO1 antibodies are available for research applications?

Based on the search results, there are several types of AVO1 antibodies available for research purposes. Particularly, polyclonal antibodies against AVO1 from Saccharomyces cerevisiae have been developed . These antibodies are typically:

• Host: Rabbit-derived polyclonal antibodies

• Specificity: Targeting Saccharomyces cerevisiae AVO1 protein

• Applications: Western blotting (WB) and ELISA assays

• Immunogen: Recombinant Saccharomyces cerevisiae (strain ATCC 204508/S288c) AVO1 protein

The commercially available antibodies are generally purified through antigen affinity methods to ensure specificity and reduced background . For researchers requiring custom AVO1 antibodies, some companies offer specialized services for specific experimental needs .

What experimental applications are best suited for AVO1 antibodies?

AVO1 antibodies can be utilized in multiple experimental applications in yeast research:

• Western Blotting (WB): For detecting and quantifying AVO1 protein expression levels in cell lysates. This application is particularly useful for studying changes in AVO1 expression under different experimental conditions or in mutant strains .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of AVO1 in protein samples. This method allows for sensitive detection of AVO1 in complex biological samples .

• Co-Immunoprecipitation (Co-IP): Essential for studying protein-protein interactions between AVO1 and other TORC2 components or interacting partners like Ypk2. Research has demonstrated successful use of this technique to characterize the AVO1-Ypk2 interaction .

• Immunofluorescence Microscopy: While not explicitly mentioned in the search results for AVO1, this technique can potentially be used to visualize the subcellular localization of AVO1 as part of the membrane-associated TORC2 complex.

How can I validate the specificity of an AVO1 antibody?

For rigorous scientific research, validating antibody specificity is crucial. For AVO1 antibodies, consider the following validation methods:

• Positive and Negative Controls:

  • Positive control: Use yeast strains expressing tagged AVO1 (e.g., HA-tagged or GFP-tagged) to confirm antibody detection .

  • Negative control: Test the antibody in avo1 deletion mutants or knockdown strains (if viable with supporting plasmids).

• Western Blot Analysis:

  • Verify a single specific band of the expected molecular weight (approximately 130 kDa for AVO1).

  • Compare band intensity across different strain backgrounds with known AVO1 expression levels.

• Blocking Peptide Competition:

  • Pre-incubate the antibody with the immunizing peptide or recombinant AVO1 protein before Western blotting.

  • A specific antibody will show reduced or eliminated signal when pre-blocked with the specific antigen.

• Testing in Various Experimental Conditions:

  • Verify reactivity across different sample preparation methods.

  • Test antibody performance in different buffer conditions to optimize signal-to-noise ratio.

How can AVO1 antibodies be used to study TORC2 signaling dynamics?

AVO1 antibodies can be powerful tools for investigating TORC2 signaling dynamics:

• Temporal Analysis of Complex Formation:

  • Use co-immunoprecipitation with AVO1 antibodies to capture TORC2 complexes at different time points following stimulation.

  • Analyze changes in complex composition using mass spectrometry to identify dynamic interactors.

• Phosphorylation-Dependent Interactions:

  • Combine AVO1 immunoprecipitation with phospho-specific antibodies (e.g., phospho-Ypk2) to track signaling events downstream of TORC2 activation.

  • Example approach: Following treatment with stress stimuli known to activate TORC2 (e.g., plasma membrane stress), analyze TORC2-dependent phosphorylation of Ypk2 using AVO1 pulldown followed by phospho-specific immunoblotting .

• Proximity-Based Labeling Approaches:

  • Combine AVO1 antibodies with BioID or APEX2 proximity labeling to map the dynamic protein interaction landscape around AVO1 under different cellular conditions.

Research has demonstrated that the AVO1-Ypk2 interaction is crucial for TORC2 signaling. Perturbation of this interaction through expression of competing protein fragments (Ypk2 334-677) disrupts TORC2-dependent Ypk2 phosphorylation, which can be detected as a loss of electrophoretic mobility shift in Ypk2 .

What methods can be used to study AVO1-Ypk2 interactions using antibodies?

To study the specific AVO1-Ypk2 interaction, researchers can employ several antibody-based approaches:

• GST Pulldown Assays:

  • Express GST-Ypk2 fusion proteins in yeast and perform pulldown assays to capture interacting proteins.

  • Use AVO1 antibodies to detect co-precipitated AVO1 by Western blotting.

  • Research has shown that GST-Ypk2, but not GST alone, can pull down TORC2 components including AVO1 .

• In Vitro Binding Assays:

  • Express recombinant AVO1 fragments and Ypk2 fragments in E. coli.

  • Use purified proteins for direct binding assays, detecting interactions with antibodies.

  • This approach has been used to map the interaction regions to amino acids 600-840 of AVO1 and the C-terminal region of Ypk2 .

• Competition Assays:

  • Employ truncated forms of proteins (e.g., Ypk2 334-677) to compete with full-length proteins for binding.

  • Use AVO1 antibodies to detect changes in interaction patterns.

  • This method has been successfully used to demonstrate that Ypk2 334-677 interferes with the AVO1-Ypk2 interaction both in vitro and in vivo .

The methodological approach described by researchers includes expressing MBP-Ypk2 bound to amylose resin, incubating with 35S-labeled AVO1, and testing competition with purified GST-Ypk2 fragments .

How can AVO1 antibodies contribute to understanding TORC2-related pathologies?

While AVO1 is primarily studied in yeast, understanding TORC2 signaling has broader implications for human health due to the high conservation of TOR signaling pathways. AVO1 antibodies can contribute to translational research through:

• Comparative Studies with Mammalian Sin1:

  • AVO1 is the yeast equivalent of mammalian Sin1, a component of mTORC2.

  • Comparative studies using AVO1 antibodies in yeast can provide mechanistic insights applicable to mTORC2 studies.

  • Understanding AVO1-Ypk2 interactions can inform studies of Sin1-SGK/Akt interactions in mammalian systems.

• Drug Discovery Applications:

  • AVO1 antibodies can be used to screen for compounds that disrupt TORC2 complex formation or function.

  • Antibody-based assays can evaluate the effects of potential therapeutic compounds on TORC2 signaling.

• Disease Modeling:

  • In humanized yeast systems expressing mammalian TORC2 components, AVO1 antibodies could be used to study the effects of disease-associated mutations on complex formation and activity.

What are common challenges when using AVO1 antibodies and how can they be addressed?

Researchers frequently encounter specific challenges when working with AVO1 antibodies:

• Cross-Reactivity Issues:

  • Challenge: Non-specific binding to other proteins in complex samples.

  • Solution: Pre-adsorb antibodies with wild-type yeast lysates from avo1 deletion strains (complemented with a plasmid for viability) to remove cross-reactive antibodies.

• Low Signal Intensity:

  • Challenge: Weak detection of endogenous AVO1.

  • Solution: Enrich TORC2 complexes through fractionation methods focusing on membrane-associated proteins, as TORC2 is primarily membrane-localized.

• Antibody Stability:

  • Challenge: Loss of antibody activity during storage.

  • Solution: Store antibodies according to manufacturer recommendations (typically at -20°C or -80°C) , avoid repeated freeze-thaw cycles, and consider adding glycerol (usually 50%) for long-term storage.

• Background in Immunoprecipitation:

  • Challenge: High background in co-IP experiments.

  • Solution: Use more stringent washing conditions or adjust antibody concentration. Consider crosslinking the antibody to beads to minimize antibody contamination in the eluate.

How should I optimize experimental conditions for AVO1 antibody applications?

Optimization of experimental conditions is crucial for successful antibody applications:

• Western Blotting Optimization:

  • Determine optimal antibody dilution through titration (typically starting with 1:500 to 1:2000 dilutions).

  • Test different blocking agents (BSA vs. non-fat dry milk) to minimize background.

  • Optimize transfer conditions for large proteins like AVO1 (1176 aa) by using low SDS concentrations and longer transfer times.

• Co-Immunoprecipitation Optimization:

  • Test different lysis buffers to preserve protein-protein interactions within the TORC2 complex.

  • Incorporate phosphatase inhibitors to maintain phosphorylation-dependent interactions.

  • Consider mild detergents (0.5-1% NP-40 or 0.5% Triton X-100) to maintain membrane-associated complex integrity.

• Sample Preparation Considerations:

  • For yeast samples, optimize spheroplasting conditions to ensure efficient cell lysis without protein degradation.

  • Use fresh samples when possible, as TORC2 components may be susceptible to proteolytic degradation.

  • Consider native vs. denaturing conditions based on experimental goals (structural studies vs. expression analysis).

How can I distinguish between AVO1 and other TORC2 components in my experiments?

When studying complex signaling pathways like TORC2, distinguishing between closely associated components is essential:

• Molecular Weight Differentiation:

  • AVO1 (1176 aa) has a distinct molecular weight from other TORC2 components:

    • Tor2: ~282 kDa

    • Avo3/Tsc11: ~164 kDa

    • AVO1: ~130 kDa

    • Lst8: ~34 kDa

    • Avo2: ~46 kDa

    • Bit61: ~61 kDa

• Sequential Immunoprecipitation:

  • Perform tandem immunoprecipitation using antibodies against different TORC2 components.

  • First, immunoprecipitate with anti-AVO1, then analyze the precipitate with antibodies against other components to verify complex formation.

• Specific Interaction Analysis:

  • Utilize the known specific interaction between AVO1 (amino acids 600-840) and Ypk2 to distinguish AVO1 from other TORC2 components.

  • Use truncated constructs of AVO1 containing only this specific region for binding studies.

How can AVO1 antibodies facilitate studies of TORC2 complex assembly and disassembly?

Understanding the dynamic nature of TORC2 assembly requires sophisticated approaches:

• Real-time Monitoring of Complex Formation:

  • Use AVO1 antibodies in conjunction with proximity-based assays (FRET, BRET, or BiFC) to monitor TORC2 assembly dynamics in response to various stimuli.

  • Apply AVO1 antibodies in super-resolution microscopy to visualize nanoscale changes in TORC2 localization and complex formation.

• Stress-Induced Complex Remodeling:

  • Apply AVO1 antibodies to track changes in TORC2 composition following cellular stresses (osmotic stress, heat shock, nutrient deprivation).

  • Compare wild-type and mutant strains to understand how complex stability is affected by specific perturbations.

• Post-translational Modification Analysis:

  • Use modified immunoprecipitation approaches with AVO1 antibodies to isolate TORC2 complexes and analyze post-translational modifications using mass spectrometry.

  • Investigate how these modifications correlate with complex assembly and signaling activity.

Research has established that TORC2 signaling is sensitive to plasma membrane stress and activates downstream kinases like Ypk1/2 . AVO1 antibodies could help track these stress-responsive changes in complex dynamics.

What is the potential for developing phospho-specific AVO1 antibodies?

Phospho-specific antibodies could provide valuable tools for studying AVO1 regulation:

• Identification of Phosphorylation Sites:

  • Use mass spectrometry to identify phosphorylation sites on AVO1 under different conditions.

  • Develop phospho-specific antibodies against key regulatory sites.

• Functional Significance of Phosphorylation:

  • Apply phospho-specific antibodies to determine how AVO1 phosphorylation correlates with:

    • TORC2 complex assembly

    • AVO1-Ypk2 binding efficiency

    • Subcellular localization of TORC2 components

• Signaling Network Analysis:

  • Use phospho-specific AVO1 antibodies to map upstream kinases and downstream consequences of AVO1 phosphorylation.

  • Investigate cross-talk between TORC2 and other signaling pathways through phosphorylation events.

While the search results don't specifically mention phospho-specific AVO1 antibodies, this approach represents an important future direction for deepening our understanding of TORC2 regulation.

How do approaches for studying AVO1 in yeast compare to studying mTORC2 components in mammalian systems?

Comparative analysis between yeast and mammalian systems reveals important parallels and differences:

• Evolutionary Conservation:

  • AVO1 is the yeast ortholog of mammalian Sin1, a critical component of mTORC2.

  • Similar experimental approaches can be applied to both systems, with yeast offering genetic tractability advantages.

• Antibody Development Considerations:

  • Mammalian systems benefit from greater commercial antibody availability.

  • Yeast systems often require custom antibody development but offer cleaner genetic backgrounds for validation.

  • Lessons from AVO1 antibody development can inform approaches for studying mTORC2 components.

• Experimental System Advantages:

  Feature	Yeast (AVO1/TORC2)	Mammalian (Sin1/mTORC2)
  Genetic manipulation	Highly tractable	More complex
  System complexity	Lower	Higher
  Conservation to humans	Moderate	High
  Antibody availability	Limited	More extensive
  Background knowledge	Extensive	Extensive

• Translational Relevance:

  • Insights from AVO1 studies in yeast have informed understanding of mTORC2 function in human cells.

  • Methodologies developed for AVO1 antibody applications can be adapted for mammalian studies.

What can we learn from antibody development strategies for other TORC2 components?

Studying antibody development for other TORC2 components provides valuable insights:

• Comparative Epitope Mapping:

  • Successful epitope mapping strategies from other antibodies (like those used for rabies virus P protein ) can be applied to AVO1.

  • These approaches include expression of deletion mutants and peptide competition assays.

• Multi-Antibody Approaches:

  • Developing antibody panels targeting different regions of AVO1, similar to approaches used for rabies phosphoprotein , could provide complementary tools for different applications.

  • This strategy enables recognition of different conformational states of the protein.

• Cross-Species Reactivity Considerations:

  • When developing antibodies against conserved regions, consider potential cross-reactivity with homologs in other species for broader application.

  • Strategic design of immunogens can enable either highly specific or intentionally cross-reactive antibodies.

How can AVO1 antibodies be incorporated into high-throughput screening approaches?

Modern research increasingly utilizes high-throughput methodologies:

• Antibody-Based Microarrays:

  • Immobilize AVO1 antibodies on microarray platforms to capture and detect TORC2 components from multiple samples simultaneously.

  • Use for screening genetic libraries or compound libraries affecting TORC2 assembly.

• Integration with Proteomics Workflows:

  • Apply AVO1 antibodies in immunoprecipitation coupled with mass spectrometry (IP-MS) for comprehensive interactome mapping.

  • Compare interactomes under different conditions to identify condition-specific interactions.

• Active Learning Approaches for Binding Analysis:

  • Utilize computational methods similar to those described for antibody-antigen binding prediction to optimize experimental design when studying AVO1 interactions.

  • These approaches can reduce experimental burden by prioritizing the most informative experiments.

What potential exists for applying AI and computational approaches to AVO1 antibody research?

Artificial intelligence and computational methods offer exciting opportunities:

• Epitope Prediction and Antibody Design:

  • Apply computational approaches similar to AbODE (Ab Initio Antibody Design using Conjoined ODEs) to predict optimal epitopes on AVO1 for antibody development.

  • These models can co-design antibody sequence and structure targeting specific AVO1 epitopes.

• Interaction Prediction:

  • Use computational methods to predict how AVO1 interacts with other TORC2 components and downstream effectors.

  • These predictions can guide antibody development targeting specific interaction interfaces.

• Active Learning for Experimental Design:

  • Implement active learning algorithms as described for antibody-antigen binding prediction to design optimal experimental approaches.

  • These methods can significantly reduce experimental costs by prioritizing the most informative experiments.

Recent research demonstrates that active learning approaches can reduce the number of required experimental samples by up to 35% while accelerating the learning process , suggesting significant potential for application to AVO1 antibody research.